P. Button

发表

Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer.

J. Jassem, A. Wardley, X. Pivot, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Vitamin D status does not predict sustained virologic response or fibrosis stage in chronic hepatitis C genotype 1 infection.

G. Dore, M. Weltman, J. George, 2013, Journal of hepatology.

Clinical utility of a blood-based EGFR mutation test in patients receiving first-line erlotinib therapy in the ENSURE, FASTACT-2, and ASPIRATION studies.

Keunchil Park, T. Mok, Yi-long Wu, 2018, Lung cancer.

Liver stiffness and the prediction of clinically significant portal hypertension and portal hypertensive complications

E. Paul, S. Roberts, M. Kitson, 2015, Scandinavian Journal of Gastroenterology.

Astodrimer sodium antiviral nasal spray for reducing respiratory infections is safe and well tolerated in a randomized controlled trial

Graham P. Heery, J. Paull, G. Kinghorn, 2022, Scientific reports.

Assessing HER2 amplification in breast cancer: findings from the Australian In Situ Hybridization Program

S. Fox, G. Farshid, M. Cummings, 2012, Breast Cancer Research and Treatment.

A Phase 2 open-label study to determine the safety and efficacy of weekly dosing of ATL1102 in patients with non-ambulatory Duchenne muscular dystrophy

P. Houweling, R. Kennedy, K. Carroll, 2022, medRxiv.

Reasons for b/tsDMARD cessation and persistence of second line treatment in a large real world rheumatoid arthritis dataset.

G. Dip., G. Littlejohn, P. Youssef, 2019, The Journal of rheumatology.

Reasons for Biologic and Targeted Synthetic Disease-modifying Antirheumatic Drug Cessation and Persistence of Second-line Treatment in a Rheumatoid Arthritis Dataset

G. Littlejohn, P. Youssef, P. Bird, 2020, The Journal of Rheumatology.

Reply to: "Vitamin D status does not predict sustained virologic response or fibrosis stage in chronic hepatitis C genotype 1 infection".

S. Roberts, M. Kitson, P. Button, 2013, Journal of hepatology.

SAT0165 Reasons for bdmard cessation and subsequent persistence of second line treatment in a large real world rheumatoid arthritis registry

G. Littlejohn, P. Youssef, P. Bird, 2018, Saturday, 16 JUNE 2018.

Pertuzumab study in the neoadjuvant setting for HER2‐positive nonmetastatic breast cancer in Australia (PeRSIA)

B. Kiely, P. Gibbs, G. Kichenadasse, 2022, International journal of cancer.

A phase II study of bevacizumab (B) and erlotinib (E) in combination for Asian patients (pts) with advanced/metastatic hepatocellular carcinoma (HCC): An interim safety report.

T. Chiou, W. Su, J. Sandoval-Tan, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A retrospective review of the persistence on bDMARDs prescribed for the treatment of rheumatoid arthritis in the Australian population

G. Littlejohn, S. Hall, P. Youssef, 2017, International journal of rheumatic diseases.

Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.

P. Marcellin, C. Yurdaydın, G. Lau, 2004, The New England journal of medicine.

Sustained response to peginterferon alfa-2a (40 kD) with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis B

G. Lau, Y. Chao, T. Tanwandee, 2008, Hepatology international.

HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa‐2a for HBeAg‐positive chronic hepatitis B

P. Marcellin, Y. Liaw, G. Lau, 2008, Hepatology.

49 Association between HBeAg seroconversion and sustained HBV-DNA suppression in patients treated with peginterferon alpha-2a (40KD) (PEGASYS) for HBeAg-positive chronic hepatitis B (CHB)

P. Marcellin, Y. Liaw, G. Lau, 2006 .

Astodrimer sodium antiviral nasal spray for reducing respiratory infections is safe and well tolerated in a randomized controlled trial

J. Paull, G. Kinghorn, C. Luscombe, 2022, Scientific reports.

Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial

Y. Bang, J. Ji, Y. Mok, 2012, The Lancet.

SP142 PD-L1 Scoring Shows High Interobserver and Intraobserver Agreement in Triple-negative Breast Carcinoma But Overall Low Percentage Agreement With Other PD-L1 Clones SP263 and 22C3

S. Fox, S. Lakhani, S. O'toole, 2021, The American journal of surgical pathology.

First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer: The ASPIRATION Study.

M. Ahn, Keunchil Park, T. Mok, 2016, JAMA oncology.

Abstract P1-12-10: Safety and efficacy of trastuzumab emtansine (T-DM1) in 399 patients with central nervous system metastases: Exploratory subgroup analysis from the KAMILLA study

P. Ellis, C. Barrios, F. Montemurro, 2017 .

Interleukin‐28B rs12979860 C allele: Protective against advanced fibrosis in chronic hepatitis C genotype 1 infection

G. Dore, M. Weltman, J. George, 2014, Journal of gastroenterology and hepatology.

1223OASPIRATION: FIRST-LINE ERLOTINIB (E) UNTIL AND BEYOND RECIST PROGRESSION (PD) IN ASIAN PATIENTS (PTS) WITH EGFR MUTATION-POSITIVE (MUT+) NSCLC.

T. Mok, V. Sriuranpong, J. Lee, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Safety of trastuzumab emtansine (T-DM1) in 373 patients 65 years or older with HER2-positive advanced breast cancer: A subgroup analysis of the Kamilla study.

P. Ellis, C. Barrios, F. Montemurro, 2015 .

Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.

P. Marcellin, C. Yurdaydın, G. Lau, 2004, The New England journal of medicine.

Effectiveness of biologics in Australian patients with rheumatoid arthritis: a large observational study: REAL

G. Littlejohn, P. Bird, L. Roberts, 2018, Internal medicine journal.

Multicenter randomized, open‐label phase II trial of sequential erlotinib and gemcitabine compared with gemcitabine monotherapy as first‐line therapy in elderly or ECOG PS two patients with advanced NSCLC

B. Solomon, S. Clarke, H. Do, 2015, Asia-Pacific journal of clinical oncology.

Tocilizumab Patterns of Use, Effectiveness, and Safety in Patients with Rheumatoid Arthritis: Final Results from a Set of Multi-National Non-Interventional Studies

L. Czirják, R. Caporali, B. Haraoui, 2019, Rheumatology and Therapy.